24 Recruiting Studies Using Tafasitamab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Tafasitamab
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
📍 MorphoSys Research Site — Daphne, Alabama
Diffuse Large B-cell Lymphoma
View Study & Checklist ➔Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
View Study & Checklist ➔Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
📍 Morristown Memorial Hospital — Morristown, New Jersey
Diffuse Large B Cell Lymphoma
View Study & Checklist ➔Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
📍 City of Hope Medical Center — Duarte, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
📍 John Muir Health Clinical Research Center — Concord, California
Follicular Lymphoma
View Study & Checklist ➔Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
📍 M D Anderson Cancer Center — Houston, Texas
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
View Study & Checklist ➔Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
📍 BCCA - Vancouver — Vancouver, British Columbia
Lymphoma, B-Cell
View Study & Checklist ➔Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
📍 Local Institution - 109 — Scottsdale, Arizona
Lymphoma, Non-Hodgkin
View Study & Checklist ➔Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Classic Follicular Lymphoma
View Study & Checklist ➔Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
📍 Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center — Cleveland, Ohio
Non Hodgkin Lymphoma
View Study & Checklist ➔TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
📍 Rhode Island Hospital — Providence, Rhode Island
Diffuse Large B Cell Lymphoma
View Study & Checklist ➔Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
📍 City of Hope Medical Center — Duarte, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
📍 Masonic Cancer Center — Minneapolis, Minnesota
Follicular Lymphoma
View Study & Checklist ➔Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
📍 University of Miami — Miami, Florida
Mantle Cell Lymphoma
View Study & Checklist ➔Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Recurrent Mantle Cell Lymphoma
View Study & Checklist ➔Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
📍 Moffitt Cancer Center — Tampa, Florida
Large B-cell Lymphoma
View Study & Checklist ➔A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
📍 M D Anderson Cancer Center — Houston, Texas
Hodgkin Lymphoma
View Study & Checklist ➔Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
📍 University of California, San Francisco — San Francisco, California
CNS Lymphoma
View Study & Checklist ➔Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
📍 Banner University Medical Center - Tucson — Tucson, Arizona
Grade 3b Follicular Lymphoma
View Study & Checklist ➔Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
📍 OHSU Knight Cancer Institute — Portland, Oregon
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
📍 Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
View Study & Checklist ➔Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
📍 MD Anderson Cancer Center — Houston, Texas
Autoimmune Disorders
View Study & Checklist ➔